Stay updated on LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial

Sign up to get notified when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Administrative updates include revision v3.4.2 and removal of revisions v3.4.1 and a government funding lapse notice; to avoid alerts for small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T02:42:00.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A government funding lapse notice has been added to the page, clarifying operational status, and the site revision version updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T00:25:36.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    A glossary toggle was added, and QC/FEAR-related metadata labels were updated to show 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', replacing the previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.
    Difference
    0.2%
    Check dated 2026-01-27T23:38:34.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T00:44:01.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    A new Locations section lists Charlottesville, Virginia as a study site. The page revision is updated to v3.3.3, and the prior Virginia Locations entry and the HHS Vulnerability Disclosure link were removed.
    Difference
    0.2%
    Check dated 2025-12-23T08:58:52.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    The page footer now displays a revision update from v3.3.1 to v3.3.2. This update does not modify substantive content or user-facing features.
    Difference
    0.1%
    Check dated 2025-12-01T16:49:53.000Z thumbnail image

Stay in the know with updates to LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.